TNGX:NASDAQTango Therapeutics, Inc. Analysis
Data as of 2026-09-01 - not real-time
$22.33
Latest Price
8/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Tango Therapeutics, Inc. is neutral at $22.33, with no clear ordering between short and long averages. Over a rolling month the price has lost 23.1%. Momentum indicators put RSI at 33.4 (approaching oversold) with MACD reading bearish. The recent range runs from support at $22.07 up to resistance at $30.25.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 100.4% above the current quote.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 54.8%, a beta of 1.45 and a maximum drawdown of 32.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 4 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 100.4% above the current quote.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 54.8%, a beta of 1.45 and a maximum drawdown of 32.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 4 out of 10.
Top Market Events
Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for...BOSTON, Aug. 06, 2026 GLOBE NEWSWIRE -- Tango Therapeutics, Inc. NASDAQ: TNGX , a clinical-stage biotechnology company...Hosted on MSN19dTNGX stock dips 5% as Q2 earnings miss estimates on higher expensesTango Therapeutics TNGX incurred a...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading above the 200-day average of 19.38
- MACD momentum is negative
- 30-day price change of -23.1%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 19.38
- Analyst targets imply +100.4% versus the current price
- 30-day volatility of 54.8%
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Negative profit margin of -229.9%
- Analyst targets imply +100.4% versus the current price
- Negative return on equity of -21.3%
Key Metrics & Analysis
Financial Health
Profit Margin-229.92%
P/E Ratio-13.7
ROE-21.34%
ROA-12.99%
Debt/Equity3.12
P/B Ratio8.2
Op. Cash Flow$-143896000
Free Cash Flow$-71874872
Industry P/E30.7
Technical Analysis
TrendNeutral
RSI33.4
Support$22.07
Resistance$30.25
MA 20$25.38
MA 50$27.49
MA 200$19.38
MACDBearish
VolumeStable
Fear & Greed Index93.52
Valuation
Target Price$44.75
Upside/Downside100.40%
GradeFair
TypeGrowth
Risk Assessment
Beta1.45
Volatility54.81%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.